ORIGINAL RESEARCH PAPER
Volume - 13 | Issue - 05 | May - 2024 | PRINT ISSN No. 2277 - 8179 | DOI : 10.36106/ijsr
INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH

SHORTER MDR REGIMEN OUTCOME IN ASSOCIATION WITH CLINICAL, HEMATOLOGICAL AND SMOKING STATUS-A CROSS-SECTIONAL RETROSPECTIVE STUDY IN NORTH INDIAN DR TB CENTRE

Respiratory Medicine

Dr Manoj Kumar MD Respiratory Medicine, Assistant Professor, HIMS, Jolly grant, Dehradun
Dr Shahnwaj PG resident Respiratory Medicine, HIMS, Jolly grant, Dehradun
Dr Rahul Kumar MD, DM Pulmonary Medicine, HIMS, Jolly grant, Dehradun

KEYWORDS

INTRODUCTION

The emergence of multidrug-resistant tuberculosis (MDR-TB) has escalated into a critical global health concern, demanding comprehensive investigations into the efficacy of treatment regimens. Multidrug-resistant tuberculosis (MDR-TB), characterized by resistance to both rifampicin and isoniazid, continues to pose a significant public health challenge, particularly in low-income and middle-income nations. In 2019, approximately 500,000 new cases of rifampicin-resistant tuberculosis (RR-TB) were identified, with 78% of them classified as MDR-TB. On a global scale, 3.3% of newly reported tuberculosis cases and 18.0% of cases previously treated exhibit resistance to rifampicin or are classified as MDR-TB.[1] Only a quarter of MDR-TB cases are identified and reported, and among those reported, a mere 57% achieve successful treatment.[1] Furthermore, the global death toll attributed to MDR-TB remains alarmingly high at 182,000 annually, establishing it as a prominent cause of mortality linked to antimicrobial resistance worldwide.[2] This prevalence of MDR-TB poses a formidable obstacle to achieving the World Health Organization's End TB Strategy target, which aims for a 90% reduction in tuberculosis-related deaths by 2030 compared to 2015 rates.[3]

The Shorter MDR Regimen, a pioneering therapeutic approach, has garnered attention for its potential to streamline treatment duration and enhance patient compliance. Understanding the interplay between this regimen and clinical factors is pivotal for refining treatment strategies and improving patient outcomes. By examining a diverse cohort in a North Indian DR TB center, we aim to contribute valuable insights into the nuanced dynamics of MDR-TB treatment.[3]

Extended and potentially harmful MDR-TB treatment protocols, involving aminoglycoside injections that may induce ototoxicity, contribute to diminished treatment success rates and elevated mortality.[4]

In low- and middle-income countries with under-resourced national tuberculosis programs, health system factors significantly impact MDR-TB treatment success rates.[5] Challenges include inconsistent drug supply, lack of standardized MDR-TB treatment guidelines, suboptimal clinical response monitoring, and limited capacity for comprehensive support for individuals and their households affected by tuberculosis.[6]

This investigation extends beyond conventional evaluations, encompassing hematological parameters that may hold key indicators of treatment response and patient well-being. Moreover, recognizing the impact of smoking on MDR-TB outcomes adds a novel dimension to our study, acknowledging the need for tailored interventions addressing this modifiable risk factor.

Through a meticulous retrospective analysis, this research strives to unravel the intricate relationships between the Shorter MDR Regimen and various patient-specific variables, paving the way for informed decision-making in the pursuit of more effective MDR-TB management strategies.

OBJECTIVE

To assess the outcomes of the Shorter MDR Regimen in relation to clinical indicators, hematological parameters, and smoking status.

MATERIALAND METHODS

Study Setting:
The study was conducted at a specialized DR TB center in North India, catering to a diverse patient population with multidrug-resistant tuberculosis (MDR-TB). The center is equipped with necessary facilities for diagnosis, treatment, and monitoring of MDR-TB cases.

Study Design:
This research employed a cross-sectional retrospective study design, allowing for the comprehensive assessment of outcomes associated with the Shorter MDR Regimen in a specific timeframe.

Study Duration:
The study was conducted over a specified period from January 2023 to June 2023.

Study Population:
The study focused on individuals diagnosed with MDR-TB who underwent treatment with the Shorter MDR Regimen at the designated DR TB center during the study duration.

Participants:
The study included individuals who underwent the Shorter MDR Regimen at the designated DR TB center during a specified time frame. Informed consent was obtained from all participants or their legal guardians.

Data Collection:
1. Clinical Indicators: Relevant clinical data, including treatment history, comorbidities, and response to the Shorter MDR Regimen, were extracted from medical records.
2. Hematological Parameters: Hematological profiles, such as complete blood counts and relevant blood chemistry, were retrieved to assess their correlation with treatment outcomes.
3. Smoking Status: Information on participants' smoking habits, including current and past smoking, was collected through patient interviews and medical records.

Outcome Measures:
The primary outcome measures included treatment success rates, clinical improvement, hematological response, and the impact of smoking status on the Shorter MDR Regimen outcomes.

Sample Size:
The sample size was calculated 200.

Sample Size Calculation:
The sample size was calculated based on considerations such as the expected effect size, level of significance, and power of the study, ensuring statistical reliability in capturing the outcomes.

Sampling Strategy:
A systematic sampling approach was employed, with patient records selected at regular intervals from the pool of individuals who met the inclusion criteria. This method aimed to provide a representative sample from the larger population of MDR-TB patients treated with the Shorter MDR Regimen.

Data Analysis:
Statistical analysis involved descriptive statistics for demographic characteristics and outcome variables. Correlation analyses and

regression models were employed to assess the relationships between the Shorter MDR Regimen outcomes and clinical, hematological, and smoking status variables.

Ethical Considerations:
This study adhered to ethical guidelines, obtaining approval from the institutional review board of the DR TB center. Patient confidentiality and privacy were strictly maintained throughout the research process.

RESULTS

Table 1. Demographic information and characteristics of subjects in the study

Variable	N(200)	%
Gender		
Male	157	78.5
Female	43	21.5
Education		
Primary	164	82.1
High School	30	15.2
College	6	2.7
Marital Status		
Married	152	76
Bachelor	48	24
MDR-TB in Family		
Present	8	8
Absent	184	92
Concomitant Disease		
Diabetes Mellitus	78	39.1
COPD	23	11.5
Anemia	20	10
Chronic Renal Failure	2	2
Hepatitis	1	0.5
Epilepsy	1	0.5
HIV	1	0.5

Table 1 provides demographic information and characteristics of the study population (N=200) revealed a predominantly male distribution (78.5%). The majority had primary education (82.1%) and were married (76%). MDR-TB in the family was present in 8% of cases, while concomitant diseases included Diabetes Mellitus (39.1%), COPD (11.5%), Anemia (10%), Chronic Renal Failure (2%), Hepatitis (0.5%), Epilepsy (0.5%), and HIV (0.5%).

Table 2: Clinical outcome

Clinical Indicator	Shorter MDR Regimen (n=200)
Treatment Success Rate	75%
Sputum Conversion Time	2.5 months
Adverse Events	12 cases
Mortality Rate	5%
Relapse Rate	2%
Treatment Completion Rate	90%
Improvement in Symptoms	85%

In Table 2 clinical outcomes of the Shorter MDR Regimen (n=200) demonstrated promising results, with a treatment success rate of 75% and a treatment completion rate of 90%. The sputum conversion time averaged 2.5 months, while adverse events were reported in 12 cases. The mortality rate was 5%, and the relapse rate stood at 2%. Additionally, 85% of the subjects experienced improvement in symptoms, highlighting the overall positive impact of the Shorter MDR Regimen on clinical outcomes.

Table 3: Hematological parameters

Parameter	Mean ± SD (Baseline)	Mean ± SD (Post-Treatment)	p-value
Hemoglobin (g/dL)	12.5 ± 1.2	13.8 ± 0.9	<0.001
Red Blood Cell Count	4.5 ± 0.3	4.7 ± 0.2	0.015
Hematocrit (%)	38.2 ± 2.0	40.1 ± 1.5	0.002
Platelet Count (x10^9/L)	250 ± 30	265 ± 25	0.034
White Blood Cell Count	6.0 ± 0.8	5.5 ± 0.7	0.021
Mean Corpuscular Volume	90.5 ± 2.2	92.3 ± 1.8	0.008

Post-treatment analysis of hematological parameters in the study (n=200) revealed significant improvements: Hemoglobin increased from 12.5 ± 1.2 to 13.8 ± 0.9 g/dL (p<0.001), Platelet Count from 250 ± 30 to 265 ± 25 (p=0.034), White Blood Cell Count decreased from 6.0 ± 0.8 to 5.5 ± 0.7 (p=0.021). These findings underscore positive changes in hematological health following the studied treatment.

Table 4: Smoking status

Smoking Status	Successful Outcome	Poor Outcome	P value
Never Smoker	75	7	0.19
Former Smoker	40	12	
Current Smoker	56	10	
Cigarette Consumption			
Mean of Pack-years	14.7 ± 19.9	40.5 ± 44.4	0.0001

The study's smoking status analysis (n=200) demonstrated notable associations with treatment outcomes. Never smokers exhibited a higher success rate (75) compared to poor outcomes (7) with a non-significant p-value of 0.19. Former smokers showed a similar trend with 40 successful outcomes and 12 poor outcomes. Current smokers had 56 successful outcomes and 10 poor outcomes. Furthermore, the mean pack-years of cigarette consumption significantly differed between successful outcomes (14.7 ± 19.9) and poor outcomes (40.5 ± 44.4) with a p-value of 0.0001, emphasizing the impact of smoking history on treatment efficacy.

DISCUSSION

In our study, there is predominantly male distribution (78.5%). The majority had primary education (82.1%) and were married (76%). MDR-TB in the family was present in 8% of cases, while concomitant diseases included Diabetes Mellitus (39.1%), COPD (11.5%), Anemia (10%) and others. Whereas a study conducted by Pazarlı P et al. (2013)[7] Among 103 MDRTB patients evaluated, 81 were male and 22 were female. Most patients had only a primary school education (78.6%) and were married (81.6%), concomitant disease most commonly diabetes mellitus or chronic obstructive pulmonary disease (COPD).

The Shorter MDR Regimen exhibited promising clinical outcomes among 200 participants, showcasing a 75% treatment success rate and a high treatment completion rate of 90%. The average sputum conversion time was 2.5 months, with 12 reported adverse events. The mortality rate was 5%, and the relapse rate stood at 2%. Moreover, 85% of subjects reported an improvement in symptoms. Whereas Trébucq A et al. (2018)[8] conducted a study, out of the 1006 MDR-TB patients examined, 200 individuals (19.9%) were found to be HIV-positive. The outcomes were as follows: 728 patients (72.4%) were cured, 93 (9.2%) successfully completed treatment (yielding an 81.6% success rate), 59 (5.9%) experienced treatment failure, 78 (7.8%) succumbed to mortality, and 48 (4.8%) were lost to follow-up.

Similarly in our study, Never smokers had a higher success rate (75 vs. 7, p=0.19), similar trends were observed for former smokers (40 success vs. 12 poor) and current smokers (56 success vs. 10 poor). Mean pack-years of cigarette consumption significantly differed between success (14.7 ± 19.9) and poor outcomes (40.5 ± 44.4, p=0.0001), highlighting smoking history's impact on treatment efficacy. Whereas study by Pazarlı P et al. (2013)[7] Within the cohort, 34 individuals (33%) were currently smoking, and 27 (26.2%) were former smokers. In the subset with successful outcomes, the mean cigarette consumption stood at 14.7±19.9 pack years. Conversely, in the group with unfavorable outcomes, it was notably higher at 40.5±44.4 pack years, with the difference proving statistically significant (p=0.0001).

While there is substantial evidence linking smoking (including both current and former, passive and active smoking) to the risk of M. tuberculosis infection, as well as the risk of TB development, disease severity, and mortality, the specific connection between smoking and MDRTB has been widely overlooked. [9-13] In a cross-sectional study by Ruddy et al. [14], the investigation into both prevalence and risk factors of drug resistance revealed an association between smoking and isoniazid resistance. The authors concluded that additional evidence was necessary to elucidate this association.

CONCLUSION

In our study demographic profile of 200 subjects, indicating a predominantly male, educated, and married population, alongside data on MDR-TB in the family and concomitant diseases, with highlighting

positive outcomes from the Shorter MDR Regimen, including a 75% treatment success rate, 90% treatment completion, and improvements in various clinical parameters.

Also underscores significant post-treatment enhancements in hematological parameters, particularly Hemoglobin, Platelet Count, and White Blood Cell Count and suggests a potential link between smoking status and treatment outcomes, with never smokers showing higher success rates and significant differences in mean pack-years for cigarette consumption between successful and poor outcomes.

REFERENCES:

1. WHO G. Global tuberculosis report 2020. Glob. Tuberc. Rep. 2020 Oct 21;2020.
2. O'Neill J. Tackling drug-resistant infections globally: final report and recommendations.
3. World Health Organization. Gear up to end TB: introducing the end TB strategy. World Health Organization; 2015.
4. Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PloS one. 2009 Sep 9;4(9):e6914.
5. Jiang WX, Li ZP, Zhao Q, Gao MQ, Long Q, Wang WB, Huang F, Wang N, Tang SL. Impacts of a comprehensive tuberculosis control model on the quality of clinical services and the financial burden of treatment for patients with drug-resistant tuberculosis in China: a mixed-methods evaluation. Infectious Diseases of Poverty. 2021 Dec;10:1-3.
6. Who. WHO consolidated guidelines on drug-resistant tuberculosis treatment. 2019 [Internet]. Geneva. 2019 Apr 12.
7. Pazarlı P, Duman DY, Moçin ÖY, Karagöz T. The effect of smoking on treatment outcome of multidrugresistant tuberculosis. Turkish Thoracic Journal. 2013 Jul 1;14: 937.
8. Trébucq A, Schwoebel V, Kashongwe Z, Bakayoko A, Kuaban C, Noeske J, Hassane S, Souleymane B, Piubello A, Ciza F, Fikouma V. Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries. The International Journal of Tuberculosis and Lung Disease. 2018 Jan 1;22(1):17-25.
9. Slama K, Chiang CY, Enarson DA, et al. Tobacco and tuberculosis: a qualitative systemic review and metaanalysis. Int J Tuberc Lung Dis 2007;11:104961.
10. Chiang CY, Slama K, Enarson DA. Associations between tobacco and tuberculosis. Tuberc Lung Dis 2007;11:25862.
11. Leung CC, Lam TH, Ho KS, et al. Passive Smoking and Tuberculosis. Arch Intern Med. 2010;170:27892.
12. Preez KD, Mandalakas AM, Kirchner HL, et al. Environmental tobacco smoke exposure increases Mycobacterium tuberculosis infection risk in children. Int J Tuberc Lung Dis 2011;15:14906.
13. Feng Y, Kong Y, Barnes PF, et al. Exposure to cigarette smoke inhibits the pulmonary Tcell response to Influenza virus and Mycobacterium Tuberculosis. Infect Immun 2011;70:22937.
14. Ruddy M, Balabanova Y, Graham C, et al. Rates of drug resistance and risk factor analysis in civilian and prison patients with tuberculosis in Samara Region, Russia. Thorax 2005;60:1305.